A significant increase in litigation has emerged as several Big Pharma companies have recently filed lawsuits against five states over drug discount programs. These lawsuits contend that the states are essentially implementing requirements that The Department of Health and Human Services (HHS) had previously attempted to enforce via guidance. This legal battle highlights ongoing tension between state-level health policies and federal regulation, further complicating the landscape for pharmaceutical companies navigating compliance and operational risks.
For more detailed information, the original coverage can be found here.